Endocannabinoid Modulation of Dopaminergic Motor Circuits by Teresa Morera-Herreras et al.
MINI REVIEW ARTICLE
published: June 2012
doi: 10.3389/fphar.2012.00110
Endocannabinoid modulation of dopaminergic motor
circuits
Teresa Morera-Herreras1,2*, Cristina Miguelez1, Asier Aristieta1, José Ángel Ruiz-Ortega1,2 and Luisa Ugedo1
1 Faculty of Medicine and Dentistry, Department of Pharmacology, University of the Basque Country, Leioa, Spain
2 Faculty of Pharmacy, Department of Pharmacology, University of the Basque Country, Vitoria-Gasteiz, Spain
Edited by:
Joseph F. Cheer, University of
Maryland School of Medicine, USA
Reviewed by:
David M. Lovinger, National Institutes
of Health, USA
Kuei-YuanTseng, Rosalind Franklin
University of Medicine and Science,
USA
*Correspondence:
Teresa Morera-Herreras, Faculty of
Pharmacy, Department of
Pharmacology, University of the
Basque Country, 01006
Vitoria-Gasteiz, Spain.
e-mail: teresa.morera@ehu.es
There is substantial evidence supporting a role for the endocannabinoid system as a mod-
ulator of the dopaminergic activity in the basal ganglia, a forebrain system that integrates
cortical information to coordinate motor activity regulating signals. In fact, the adminis-
tration of plant-derived, synthetic or endogenous cannabinoids produces several effects
on motor function. These effects are mediated primarily through the CB1 receptors that
are densely located in the dopamine-enriched basal ganglia networks, suggesting that the
motor effects of endocannabinoids are due, at least in part, to modulation of dopaminergic
transmission. On the other hand, there are profound changes in CB1 receptor cannabinoid
signaling in the basal ganglia circuits after dopamine depletion (as happens in Parkinson’s
disease) and following l-DOPA replacement therapy.Therefore, it has been suggested that
endocannabinoid system modulation may constitute an important component in new ther-
apeutic approaches to the treatment of motor disturbances. In this article we will review
studies supporting the endocannabinoid modulation of dopaminergic motor circuits.
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The discovery and the following investigation of the endocannabi-
noid system have demonstrated its implication in a large variety of
functions such as regulation of appetite and energy metabolism,
pain and inﬂammation, neuroprotection, and motor control. The
endocannabinoid system is also a modulator of the basal ganglia
circuitry functionality (Benarroch, 2007; Fernandez-Ruiz, 2009)
and therefore, it may be considered as a potential pharmacolog-
ical target for the treatment of movement disorders. This review
is focused on the endocannabinoid modulation of dopaminergic
motor circuits.
NEUROANATOMICAL EVIDENCES SUPPORTING
DOPAMINERGIC-ENDOCANNABINOID INTERACTION
The cannabinoid receptors, endocannabinoids and the proteins
for their biosynthesis and degradation constitute the key compo-
nents of the endocannabinoid system (Di Marzo et al., 1998). CB1
receptors and endocannabinoids are highly expressed in the basal
ganglia and have close connections with the dopaminergic system,
being involved in the central regulation of motor functions.
To date, two cannabinoid receptor subtypes have been iden-
tiﬁed by molecular cloning, cannabinoid receptor type 1 (CB1)
(Matsuda et al., 1990) and cannabinoid receptor type 2 (CB2)
(Munro et al., 1993). The vastmajority of CB1 receptors are located
in the central nervous system while CB2 receptors are expressed
primarily in cells of the immune system (Munro et al., 1993),
microglia, blood vessels and some neurons (Van Sickle et al., 2005;
Gong et al., 2006). Both CB1 and CB2 are seven transmembrane
Gi/o-coupled receptors that activate similar intracellular signaling
pathways (Mackie, 2008). The discovery of the cannabinoid recep-
tors led to the identiﬁcation of the so-called natural ligands of
the cannabinoid receptors, anandamide (Devane et al., 1992) and
2-arachidonoylglycerol (2-AG) (Devane et al., 1992; Mechoulam
et al., 1995) which are synthesized “on demand” in response to
elevations of intracellular calcium (Di Marzo et al., 1994).
Although the expression of CB2 receptors has remained con-
troversial (Atwood and Mackie, 2010), mRNA for this receptor
has been found in neurons and glial cells from the substantia
nigra pars reticulata (SNpr) and the striatum (Gong et al., 2006).
As for CB1 receptor, high levels are expressed within the basal
ganglia (Herkenham et al., 1990; Mailleux and Vanderhaeghen,
1992; Tsou et al., 1998; Mackie, 2005; Martin et al., 2008). While
mRNA for this receptor is found in striatal GABAergic medium
spiny neurons (Mailleux and Vanderhaeghen, 1992) and in the
subthalamic nucleus (STN), the expression of the receptor pro-
tein is mainly located at the terminal level. Thus, CB1 receptors
have been observed in subthalamonigral and subthalamopallidal
terminals (Mailleux and Vanderhaeghen, 1992; Tsou et al., 1998),
glutamatergic corticostriatal afferences (Gerdeman and Lovinger,
2001; Kofalvi et al., 2005), and striatal projections to the globus
pallidus (GPi and GPe) and to the SNpr (Herkenham et al., 1991;
Tsou et al., 1998; Figure 1).
Neurons expressing D1 receptors form the direct pathway,
which projects to the GPi and the SNpr, while neurons express-
ing D2 receptors constitute the indirect pathway, projecting to
the GPe (Figure 1) (Paul et al., 1992; O’Connor, 1998; Nicola
et al., 2000; Onn et al., 2000; Svenningsson et al., 2000). A poten-
tial interaction between the D1/D2 and CB1 receptors at the level
on the G-protein/adenylyl cyclase signal transduction mechanism
has been suggested (Giuffrida et al., 1999; Meschler and Howlett,
2001). Combined activation of CB1 and D1 receptors results in
a net decrease in adenylyl cyclase, a subsequent decrease in the
inhibitory activity of direct striatal projection neurons and ﬁnally
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FIGURE 1 | Distribution of CB1 andTRPV1 receptors and their
coexpression with dopaminergic D1 and D2 receptors in a simplified
diagram of the basal ganglia circuits. GABAergic inhibitory pathways are
represented in blue and glutamatergic excitatory pathways in red.
Modulatory dopaminergic connections are indicated in green. CB1,
cannabinoid receptor type 1; TRPV1, transient receptor potential vanilloid
type 1; D1, dopaminergic receptor type 1; D2, dopaminergic receptor type
2; GPe, external globus pallidus; GPi, internal globus pallidus; STN,
subthalamic nucleus; SNpc, substantia nigra pars compacta; SNpr,
substantia nigra pars reticulata.
a decreased motor response due to enhanced activation of SNpr
neurons. Conversely, activation of CB1 and D2 receptors together
stimulates adenylyl cyclase (Glass and Felder, 1997), potentiating
the indirect striatal pathway neurons that in turn activate neu-
rons of the STN, also resulting in motor inhibition (Brotchie,
2003; van der Stelt and Di Marzo, 2003). These data indicate that
endocannabinoid system acting on striatal CB1 receptors play a
signiﬁcant role in the regulation of basal ganglia motor circuits.
Although CB1/D2 receptor heterodimerization has been demon-
strated in transfected cells by co-immunoprecipitation and Forster
Resonance Energy Transfer (FRET) techniques (Kearn et al., 2005;
Marcellino et al., 2008), functionality of those heteromers in stri-
atal glutamatergic terminals is not supported by recent studies
(Kreitzer and Malenka, 2007).
In the last years, the transient receptor potential vanilloid type 1
(TRPV1) has gained attention for its ability to bind cannabinoids.
Although neuronal expression and functionality of TRPV1 chan-
nels are controversial (Mezey et al., 2000; Cristino et al., 2006;
Cavanaugh et al., 2011), this receptor is present in the basal gan-
glia. Indeed, TRPV1 is located on nigrostriatal terminals and on
tyrosine hydroxylase positive cells in the substantia nigra pars
compacta (SNpc) (Mezey et al., 2000; Micale et al., 2009) which
makes it a good candidate for directly modulating dopaminer-
gic neurotransmission (Figure 1). On the other hand, the orphan
G-protein-coupled receptor 55 (GPR55) has been identiﬁed as
another possible cannabinoid receptor (Ryberg et al., 2007) that, in
contrast to classical CB1 and CB2, is coupled to Gq, Gα12 and Gα13
proteins (Sharir and Abood, 2010). Despite its high expression in
the striatum (Sawzdargo et al., 1999), conﬂicting pharmacological
ﬁndings make difﬁcult to consider the GPR55 as a novel cannabi-
noid receptor (Oka et al., 2007; Lauckner et al., 2008; Sharir and
Abood, 2010). Future investigations will clarify the role of TRPV1
and GPR55 in modulating basal ganglia circuits.
FUNCTIONAL INTERACTIONS BETWEEN
ENDOCANNABINOID AND DOPAMINERGIC SYSTEMS IN THE
BASAL GANGLIA
In accordance with its neuroanatomical distribution, functional
and behavioral studies have suggested that the endocannabi-
noid system can act as an indirect modulator of dopaminergic
neurotransmission in the basal ganglia.
BEHAVIORAL STUDIES
Several inﬂuences of cannabinoids on motor activity depend on
the cannabinoids inﬂuence on the dopaminergic system. Sys-
temic administration of synthetic and endogenous cannabinoids
(Δ9-THC, WIN 55,212-2, CP 55,940, or anandamide) character-
istically induces inhibition of motor behavior and catalepsy in
rodents (Prescott et al., 1992; Crawley et al., 1993; Navarro et al.,
1993; Anderson et al., 1995; Romero et al., 1995; de Lago et al.,
2004). Moreover, the anandamide transport inhibitor, AM404,
or inhibitors of anandamide hydrolysis produce hypokinesia in
rats (Compton and Martin, 1997; Gonzalez et al., 1999). These
hypokinetic effects can be reversed by the selective CB1 receptor
antagonist, rimonabant,which in itself causes hyperlocomotion in
healthy controls (Compton et al., 1996). In agreement with these
observations, mice lacking CB1 receptors exhibit several motor
anomalies (Ledent et al., 1999; Zimmer et al., 1999). Although
these ﬁndings provide evidence for the involvement of CB1-related
mechanisms inmotor control, other reports demonstrate that also
the TRPV1 receptors can mediate effects of certain cannabinoids
such as anandamide (de Lago et al., 2004).
It has been hypothesized that the inhibition of motor behav-
ior mediated by cannabinoids could be related to a reduction in
dopaminergic circuitry activity. Rotational studies in rats receiving
local injections of cannabinoid compounds into the basal gan-
glia suggest that dopamine-cannabinoid interaction is not a direct
mechanism. For instance,cannabinoids increase ordecreasemotor
behavior when locally administered into the direct (Sanudo-Pena
et al., 1996, 1998) or indirect pathway, respectively (Sanudo-Pena
and Walker, 1997; Miller et al., 1998). Neuroanatomical studies
showing that CB1 receptors are not present on dopaminergic neu-
rons or terminals (Julian et al., 2003; Matyas et al., 2006) suggest
that CB1-mediated modiﬁcations of nigrostriatal dopaminergic
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circuits are exerted indirectly by modulation of inhibitory or
excitatory inputs to the midbrain dopamine neurons. Indeed,
cannabinoids are known to dampen both glutamate and GABA
transmission in the basal ganglia (Szabo et al., 2000; Gerdeman
and Lovinger, 2001; Wallmichrath and Szabo, 2002).
ELECTROPHYSIOLOGICAL AND NEUROCHEMICAL STUDIES
In vivo electrophysiological studies have shown that cannabinoid
agonists increase the action potential ﬁring rate of SNpc neurons
(French et al., 1997; Melis et al., 2000; Morera-Herreras et al.,
2008). Since CB1 receptors are poorly expressed in SNpc neurons
(Julian et al., 2003; Matyas et al., 2006), or even absent, the action
of cannabinoids is indirectly exerted on dopaminergic neurons
through other nuclei. In line with this, in the SNpr the CB1 recep-
tors are located on subthalamonigral terminals and their activation
inhibits glutamate release (Szabo et al., 2000) resulting in a reduc-
tion of GABAergic transmission and, consequently, in an increased
activity of SNpc cells (Morera-Herreras et al., 2008).
The increased activity of SNpc neurons observed after CB1
receptor activation is in agreement with in vivo microdialysis
experiments showing enhanced dopamine release in the striatum
after exogenous or endogenous cannabinoid agonists administra-
tion (Tanda et al., 1997; Solinas et al., 2006). However, this effect
is not mediated locally at the terminal level, but rather involves
changes in the ﬁring activity of SNpc neurons, since in vitro stud-
ies in striatal slices have shown that CB1 activation has no effect on
dopamine release (Kofalvi et al., 2005). Contrary to CB1-mediated
mechanisms, the effects of endocannabinoids on dopamine trans-
mission may be mediated by direct mechanisms. Indeed, the
endocannabinoid anandamide and some analogs (but not classic
cannabinoid as Δ9-THC), acting via postsynaptic TRPV1 recep-
tors, may reduce nigrostriatal dopaminergic cell activity (de Lago
et al., 2004). However, other authors have reported an increase of
dopamine release after activation of TRPV1 receptors in the SNpc
(Marinelli et al., 2003, 2007), although this enhancement may be
mediated by TRPV1 receptors located in glutamatergic terminals
in the SNpc rather than by receptors located in dopaminergic
terminals.
PATHOLOGICAL IMPLICATIONS OF THE INTERACTION
BETWEEN DOPAMINE AND THE ENDOCANNABINOID
SYSTEM
As described above, neuroanatomical studies have located
cannabinoid receptors in the basal ganglia, and it iswidely accepted
that the endocannabinoid system inﬂuence physiological motor
function. These facts predict that pharmacological modulation of
the endocannabinoid system may also be beneﬁcial under patho-
logical conditions pertaining to decreased dopamine signaling or
the chronic treatment with l-DOPA.
ROLE OF THE CANNABINOID SYSTEM IN PARKINSON’S DISEASE
In Parkinson’s disease (PD), the progression of the neurodegen-
erative pathology and the appearance of major motor symptoms
are related to increased endocannabinoid levels (Pisani et al., 2005,
2010). Several studies have also found increased CB1 receptor lev-
els in the striatum of parkinsonian monkeys and human patients
(Lastres-Becker et al., 2001; Van Laere et al., 2012). In rat models
of PD, publications supporting increased (Gubellini et al., 2002;
Maccarrone et al., 2003; Gonzalez et al., 2005), decreased (Sil-
verdale et al., 2001; Ferrer et al., 2003; Walsh et al., 2010b), or no
modiﬁcation (Romero et al., 2000; Kreitzer and Malenka, 2007)
of endocannabinoid tone have been reported. The heterogeneous
results obtained in animal models may depend on methodologi-
cal differences such as the way of inducing parkinsonism or more
importantly on the period of recovery after the lesion before
performing experiments (Romero et al., 2000).
Studies in animal models and patients of PD have indicated
that dopaminergic neuronal degeneration produces an imbalance
between the direct and the indirect basal ganglia pathways. This
imbalance is manifested as reduced activity of striatal GABAergic
neurons in the direct pathway and hyperactivity in the indirect
pathway striatal neurons. Moreover, glutamatergic input from the
cortex to the striatum is augmented after dopaminergic denerva-
tion (Tang et al., 2001; Tseng et al., 2001;Gubellini et al., 2002;Mal-
let et al., 2006). Within the basal ganglia, CB1 receptors are prin-
cipally expressed on presynaptic cortical glutamatergic terminals
and presynaptic striatal GABAergic terminals (Benarroch, 2007).
The activation of CB1 receptors reduces the glutamate release
from the cortex to the striatum (Gerdeman and Lovinger, 2001;
Gubellini et al., 2002; Brown et al., 2003) and GABA release to the
SNpr (Wallmichrath and Szabo, 2002). In addition, endocannabi-
noids and CB1 receptors play an important physiological role in
the long- and short-termregulationof the synaptic transmission in
the basal ganglia shaping the striatal output and therefore modu-
latingmotor activities. The two classic forms of long-term synaptic
plasticity, long-termpotentiation and long-termdepression (LTD)
are expressed at corticostriatal synapses and abolished in animal
models of PD (Centonze et al., 1999; Picconi et al., 2005; Calabresi
et al., 2007; Kreitzer and Malenka, 2007). Using different LTD
induction paradigms it has been described that this form of plas-
ticity is mostly controlled by endocannabinoids (Shen et al., 2008;
Lovinger, 2010). Although probably other mechanisms are also
involved in the dopaminergic control of striatal plasticity, phar-
macological manipulation of the endocannabinoid system under
parkinsonian conditions has been proved not only to rescue LTD
in striatum but also to improve the motor deﬁcits evident after
dopaminergic denervation (Kreitzer and Malenka, 2007).
In line with this, behavioral studies have shown that mod-
ulation of the endocannabinoid system can have a therapeutic
impact in animal models of PD. Behavioral changes caused by
the induction of parkinsonism in rats have been improved by
the administration of CB1 receptor antagonists both in unilat-
eral and bilateral PD models in rodents (Fernandez-Espejo et al.,
2005; Gonzalez et al., 2006; Kelsey et al., 2009). In MPTP-lesioned
marmosets, CB1 antagonist administration increased locomotor
activity but failed to improve bradykinesia or posture (van der Stelt
et al., 2005). On the other hand, co-administration of l-DOPA
with CB1 antagonists added a positive improvement of the motor
symptoms assigned to the antiparkinsonian drug in parkinsonian
animals (Kelsey et al., 2009). The latter data suggest that combined
therapy with antiparkinsonian drugs and cannabinoid antagonists
may permit a reduction of l-DOPA dose and therefore, delay
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the emergence of the motor side effects induced by the chronic
treatment with l-DOPA.
The beneﬁt of cannabinoids in PD is not limited to the sympto-
matic amelioration. Lately, several reports have revealed interest-
ing neuroprotective and anti-inﬂammatory effects of these drugs
in cell cultures and animal models of PD (Lastres-Becker et al.,
2005; Garcia-Arencibia et al., 2007; Fernandez-Ruiz et al., 2011;
Jeon et al., 2011; Carroll et al., 2012). Although CB1 receptor-
mediated effects cannot be excluded, some authors argue that
CB1 receptorsmay have aminimal implication in neuroprotection
(Lastres-Becker et al., 2005; Fernandez-Ruiz et al., 2007; Price et al.,
2009;Chung et al., 2011). It seemsplausible that neuroprotection is
principallymediated by the antioxidant effect of cannabinoids and
CB1 receptor-independent properties (Lastres-Becker et al., 2005;
Garcia-Arencibia et al., 2007; Carroll et al., 2012), while in paral-
lel, activation of CB2 receptors in astrocytes and microglial cells is
responsible for the observed anti-inﬂammatory effect. Although
the exact mechanisms should be further investigated, cannabi-
noid receptor modulation can be potentially useful for protecting
dopaminergic neurons fromprogressive neurodegeneration inPD.
IMPLICATION OF THE CANNABINOID SYSTEM IN L-DOPA INDUCED
DYSKINESIA
The emerging role of the endocannabinoid system as modulator
of neurotransmission in the basal ganglia identiﬁes it as a potential
pharmacological target for treating motor complications derived
from the chronic treatment with l-DOPA. l-DOPA induced dysk-
inesia (LID) constitute one of the most disabling complications
derived from the long-term therapy with l-DOPA affecting up
to 40% of PD patients after 5 years of treatment (Ahlskog and
Muenter, 2001). Cannabinoid agonists could exert antidyskinetic
effect by regulating glutamatergic release in the striatum and/or
by re-establishing endocannabinoid-mediated synaptic plasticity
affected by dopaminergic denervation. In this sense, pharmaco-
logical agents with antidyskinetic properties such as serotonergic
5-HT1B agonists are able to ameliorate themotor complications by
depressing the glutamatergic corticostriatal transmission (Mathur
et al., 2011).
Cannabinoid agents have been proposed as promising tools
for treating LID, however, different studies in animal models and
patients show certain discrepancies. Administration of cannabi-
noid agonists to parkinsonian rats receiving chronic l-DOPA
treatment attenuated LID via CB1-related mechanisms (Ferrer
et al., 2003; Morgese et al., 2007; Martinez et al., 2012) and genetic
deletion of CB1 receptors prevented the development of severe
dyskinetic movements in mice (Perez-Rial et al., 2011). Although
the cited studies do not report any reduction of the efﬁcacy of
l-DOPA to improve the motor performance, a recent publica-
tion suggests that the antidyskinetic effect of cannabinoid agonists
seem to be based on their general motor suppressant (Walsh
et al., 2010a). In MPTP-lesioned monkeys and PD patients con-
tradictory results have been found since CB1 receptor activation
(Silverdale et al., 2001; Fox et al., 2002) or blockage (van der Stelt
et al., 2005) ameliorated LID. Other studies in patients have failed
to ﬁnd any correlation betweenCB1 receptor expression and sever-
ity of dyskinesia (van der Stelt et al., 2005) or attribute any positive
effect of cannabinoid agent administration in LID (Carroll et al.,
2004; Mesnage et al., 2004).
Taken together, changes in the cannabinoid system are observed
after dopaminergic denervation and manipulation of this system
has proved to have beneﬁcial effects on parkinsonian symptoms
in animal models and PD patients. However, the putative role of
cannabinoids in LID is still a matter of controversy. The complex
localization of the cannabinoid receptors at different sites in the
basal ganglia circuits may contribute to the paradoxical observed
effects. Further investigations are needed to clarify the role of the
cannabinoid system in LID.
In conclusion, the endocannabinoid system modulates nigros-
triatal dopamine transmission both via direct and indirect mech-
anisms. This system has an important role in dopamine-related
movement disorders, as PD, and represents a framework for novel
therapeutic approaches in the future.
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